DexCom (NASDAQ:DXCM) Given New $86.00 Price Target at Sanford C. Bernstein

DexCom (NASDAQ:DXCM) had its price objective boosted by Sanford C. Bernstein from $82.00 to $86.00 in a report published on Friday morning, Benzinga reports. The firm currently has an outperform rating on the medical device company’s stock.

Several other equities research analysts also recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Robert W. Baird upped their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Raymond James reduced their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday. JPMorgan Chase & Co. upped their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday. Finally, Leerink Partners cut their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday. Six investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Down 1.9 %

DexCom stock opened at $73.44 on Friday. The company has a 50-day simple moving average of $70.11 and a 200-day simple moving average of $98.24. The firm has a market capitalization of $29.21 billion, a P/E ratio of 47.38, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom has a one year low of $62.34 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. The business had revenue of $994.20 million during the quarter, compared to analyst estimates of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. As a group, equities analysts expect that DexCom will post 1.69 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,824 shares of company stock worth $126,390. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of large investors have recently made changes to their positions in DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom in the 2nd quarter valued at about $25,000. Sachetta LLC raised its position in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares in the last quarter. Crewe Advisors LLC bought a new position in DexCom during the first quarter valued at approximately $29,000. Riverview Trust Co raised its position in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC raised its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.